The underlying pathophysiology and therapeutic approaches for osteoporosis

被引:78
作者
Awasthi, Harshika [1 ]
Mani, Dayanandan [1 ]
Singh, Divya [2 ]
Gupta, Atul [3 ]
机构
[1] CSIR Cent Inst Med & Aromat Plants, Herbal Med Prod, Lucknow, Uttar Pradesh, India
[2] CSIR Cent Drug Res Inst, Div Endocrinol, Lucknow, Uttar Pradesh, India
[3] CSIR Cent Inst Med & Aromat Plants, Med Chem Dept, PO CIMAP,Kukrail Rd, Lucknow 226015, Uttar Pradesh, India
关键词
anabolic agents; antiresorptive therapies; novel targets; osteoporosis; pathophysiology; triggers and targets; HORMONE-REPLACEMENT THERAPY; BONE-MINERAL DENSITY; ESTROGEN-RECEPTOR MODULATORS; GLUCOCORTICOID-INDUCED OSTEOPOROSIS; NANOPARTICLE BASED FORMULATION; ENDOTHELIAL GROWTH-FACTOR; CALCIUM-SENSING RECEPTOR; CATHEPSIN-K INHIBITORS; LONG-TERM EXTENSION; VITAMIN-D-RECEPTOR;
D O I
10.1002/med.21504
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
With an increase in the ageing population worldwide, the prevalence of osteoporosis increases at an alarming rate in both male and female irrespective of their ethnicity. At present, the currently available therapeutic options are mostly limited to either bone resorptive or bone forming efficacies and both approaches are associated with serious side effects. Despite these options, there is still need for newer therapeutics to treat osteoporosis, which can offer beneficial effects for maintaining balanced dynamics between bone formation and bone resorption, devoid of any side effect. The proper understanding of pathophysiology of the disease is essential for designing or investigating an effective and safe anti-osteoporotic agent. This review represents a discussion around the molecular targets with their implications in disease progression, available therapeutic options, the emerging targets, and the importance of designing an effective anti-osteoporotic agent.
引用
收藏
页码:2024 / 2057
页数:34
相关论文
共 248 条
[1]  
Abdel-Magid Ahmed F, 2015, ACS Med Chem Lett, V6, P628, DOI 10.1021/acsmedchemlett.5b00189
[2]   NF-κB signaling and bone resorption [J].
Abu-Amer, Y. .
OSTEOPOROSIS INTERNATIONAL, 2013, 24 (09) :2377-2386
[3]   Osteoporosis in men: a review [J].
Adler, Robert A. .
BONE RESEARCH, 2014, 2
[4]  
ALEXEEVA L, 1994, WHO TECH REP SER, V843, P1
[5]   Emerging Targets in Osteoporosis Disease Modification [J].
Allen, John G. ;
Fotsch, Christopher ;
Babij, Philip .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (11) :4332-4353
[6]   ESTROGENS AND ANDROGENS IN SKELETAL PHYSIOLOGY AND PATHOPHYSIOLOGY [J].
Almeida, Maria ;
Laurent, Michael R. ;
Dubois, Vanessa ;
Claessens, Frank ;
O'Brien, Charles A. ;
Bouillon, Roger ;
Vanderschueren, Dirk ;
Manolagas, Stavros C. .
PHYSIOLOGICAL REVIEWS, 2017, 97 (01) :135-187
[7]   Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab [J].
Anastasilakis, Athanasios D. ;
Toulis, Konstantinos A. ;
Polyzos, Stergios A. ;
Anastasilakis, Chrysostomos D. ;
Makras, Polyzois .
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2012, 8 :295-306
[8]   EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair [J].
Arthur, Agnieszka ;
Panagopoulos, Romana A. ;
Cooper, Lachlan ;
Menicanin, Danijela ;
Parkinson, Ian H. ;
Codrington, John D. ;
Vandyke, Kate ;
Zannettino, Andrew C. W. ;
Koblar, Simon A. ;
Sims, Natalie A. ;
Matsuo, Koichi ;
Gronthos, Stan .
JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28 (04) :926-935
[9]   Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans [J].
Aslan, Derya ;
Andersen, Mille Dahl ;
Gede, Lene Bjerring ;
de Franca, Tine Kellemann ;
Jorgensen, Sara Rubek ;
Schwarz, Peter ;
Jorgensen, Niklas Rye .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2012, 72 (01) :14-22
[10]  
Augoulea A, 2017, J MUSCULOSKEL NEURON, V17, P444